Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Girl in a jacket

Guerbet in India and 100 Years & Beyond of Lipiodol

: 29-Jan-2022     : AP     Source : Microbioz Health

Guerbet (FR0000032526 GBT), a global leader in medical imaging, hosted its first India virtual media roundtable today, titled ‘Guerbet in India and 100 Years & Beyond of Lipiodol’.

Lipiodol is internationally recognized as one of the foremost ethiodized oil that has transformed lives and contributed to huge advances in the treatment of major diseases and debilitating conditions. In India, the drug has been used in fighting liver cancer and disease for decades and continues to make contributions to the management of various diseases.

Lipiodol is a pale yellow/amber-coloured, oil-based, radiopaque contrast agent consisting of iodine that is organically combined with ethyl esters of fatty acids of poppy seed oil. It was first synthesized in 1901 by French pharmacist Marcel Guerbet initially for therapeutic use. Then in 1921 Lipiodol® (ethiodized oil) was discovered for the use of radiology, till date this injection is a prescription oil-based radio-opaque contrast agent indicated for conventional trans-arterial chemo-embolization (cTACE), diagnosis liver lesions, vascular embolization with medical cyanoacrylate glues, lymphography and endocrinology in adult as well as pediatric patients.

From top to bottom, left to right: Mathieu Elie, Chief Commercial Officer at Guerbet, Asia Pacific, Dr. Sanjay Saran Baijal, Chairman of Diagnostics & Interventional Radiology, Medanta – The Medicity (Gurugram), Jade Ollerenshaw from Guerbet, Australia (Facilitator), Ghosh TP, General Manager at Guerbet, India, Dr. Vimal Someshwar, Head of Department, Intervention & Diagnostic Radiology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute (Mumbai)

In attendance were Dr. Sanjay Saran Baijal, Chairman of Diagnostics & Interventional Radiology at the Medanta – The Medicity, Dr. Vimal Someshwar, Head of Department, Intervention & Diagnostic Radiology, at the Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Ghosh TP, General Manager, India at Guerbet and Mathieu Elie, Chief Commercial Officer (CCO), Asia Pacific at Guerbet. The panellists discussed Lipiodol’s effect on disease management across India and beyond, and its use and future application in the country.

Both Dr. Vimal Someshwar and Dr. Sanjay Saran Baijal gave presentations relating to the use of Lipiodol in disease management. Dr. Baijal presented on ‘Lipiodol – Management of Hepatocellular Carcinoma (HCC) & as the Foundation for Lymphatic Interventions’, while Dr. Someshwar gave an overview of his ‘Lipiodol: Comprehensive Indications’ research and work.

Ghosh TP, General Manager, Guerbet, India outlined Guerbet’s business in India which set up the inauguration of Guerbet India’s Head Office in Mumbai in October 2021, while Mathieu Elie, CCO, Asia Pacific, shared detail on Guerbet’s wider business across the Asia Pacific region and highlighted the importance of the India market is to Guerbet.

Categories: Health Business | Comments
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments